Page last updated: 2024-11-01

niclosamide and Adenocarcinoma of Lung

niclosamide has been researched along with Adenocarcinoma of Lung in 1 studies

Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.

Adenocarcinoma of Lung: A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stewart, RL1
Carpenter, BL1
West, DS1
Knifley, T1
Liu, L1
Wang, C1
Weiss, HL1
Gal, TS1
Durbin, EB1
Arnold, SM1
O'Connor, KL1
Chen, M1

Other Studies

1 other study available for niclosamide and Adenocarcinoma of Lung

ArticleYear
S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell

2016